Successfully Improve Quality, Consistency & Cost of Your Raw Materials to Develop Regulatory Compliant, Efficacious & Scalable Cell & Gene Therapies for Patients in Need

Raw materials play a critical role in the development of cell and gene therapies and their quality directly affects the stability, safety, potency, and purity of cell and gene products. However, selection, understanding and lifecycle management of raw materials in line with regulatory expectations remains challenging.

This November, the inaugural Raw Materials for Cell & Gene Therapy Summit will emerge as the industry’s exclusive and timely opportunity to address these challenges and bridge the knowledge gap within the raw material community as we delve into critical issues such as supplier selection, material quality, safety assurance and required good manufacturing practices for materials to develop regulatory compliant and high-quality cell and gene therapies.

Navigating through discussions and case studies covering protein and enzyme-based materials, single-use technologies and beyond, join VP, Heads and Directors of Raw Material, Process Development, Quality Control and CMC experts from leading Biopharma, Coordinating Bodies, Suppliers, and CRO’s to address the complexity in defining, selecting, using, and adhering to multifaceted regulatory requirements for cell and gene materials towards addressing the unmet clinical need across the globe.

Don’t miss out on the opportunity to join the likes of Roche, BMS and Standards Coordinating Body to establish unified definitions for raw materials, ensure global alignment and streamline the development and regulatory approvals of new and innovative cell and gene therapies for patients.